Major Depressive Disorder

Latest News

Sebastien Montier/AdobeStock
AXS-05 Demonstrates Efficacy and Manageable Adverse Effects in Major Depressive Disorder Treatment

February 12th 2025

A pooled analysis of two clinical trials highlights AXS-05’s rapid and sustained effectiveness in reducing depressive symptoms, offering a promising new treatment option for major depressive disorder with a manageable safety profile.

Yuparet/AdobeStock
SPN-820 Shows Rapid and Significant Improvement in Major Depressive Disorder Symptoms

February 12th 2025

psychedelic
CYB003 for the Adjunctive Treatment of Major Depressive Disorder

February 10th 2025

Major Depressive Disorder Research Roundup: February 6, 2025
Major Depressive Disorder Research Roundup: February 6, 2025

February 6th 2025

Maxx Studio/Shutterstock
Positive Results in Phase 2b Trial of Psychedelic Agent GH001 for Treatment-Resistant Depression

February 4th 2025

Latest CME Events & Activities

More Than ‘Blue’ After Birth: Managing Diagnosis and Treatment of Post-Partum Depression

View More

Patient, Provider & Caregiver Connection™: Reducing the Burden of Parkinson Disease Psychosis with Personalized Management Plans

View More

Expert Perspectives in the Recognition and Management of Postpartum Depression

View More

Southern California Psychiatry Conference

July 11-12, 2025

Register Now!

SimulatED™: Diagnosing and Treating Alzheimer’s Disease in the Modern Era

View More

Expert Illustrations & Commentaries™: New Targets for Treatment in Cognitive Impairment in Schizophrenia – The Role of NMDA Receptors and Co-agonists

View More

BURST CME™ Part I: Understanding the Impact of Huntington’s Disease

View More

Burst CME™ Part II: The Evolving Treatment Landscape for Huntington Disease

View More

Clinical ShowCase: Developing a Personalized Treatment Plan for a Patient with Huntington’s Disease Associated Chorea

View More

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

View More

Community Practice Connections™: Optimizing the Management of Tardive Dyskinesia—Addressing the Complexity of Care With Targeted Treatment

View More

PER Psych Summit: Integrating Shared Decision-Making Into Management Plans for Patients With Schizophrenia

View More

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

View More

More News

© 2025 MJH Life Sciences

All rights reserved.